Mp16-10 Safety and Efficacy of Intensive Instillation of Low-Dose Pirarubicin vs. Bacillus Calmette-Guérin in High-Risk Non-Muscle-Invasive Bladder Cancer

You have accessJournal of UrologyBladder Cancer: Non-invasive I (MP16)1 May 2024MP16-10 SAFETY AND EFFICACY OF INTENSIVE INSTILLATION OF LOW-DOSE PIRARUBICIN VS. BACILLUS CALMETTE-GUÉRIN IN HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER Naoki Fujita, Masaki Momota, Takuma Narita, Hiroyuki Ito, Takahiro Yoneyama, Yasuhiro Hashimoto, Kazuaki Yoshikawa, Chikara Ohyama, and Shingo Hatakeyama Naoki FujitaNaoki Fujita , Masaki MomotaMasaki Momota , Takuma NaritaTakuma Narita , Hiroyuki ItoHiroyuki Ito , Takahiro YoneyamaTakahiro Yoneyama , Yasuhiro HashimotoYasuhiro Hashimoto , Kazuaki YoshikawaKazuaki Yoshikawa , Chikara OhyamaChikara Ohyama , and Shingo HatakeyamaShingo Hatakeyama View All Author Informationhttps://doi.org/10.1097/01.JU.0001008640.01272.9d.10AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To evaluate the safety and efficacy of intensive intravesical instillation of low-dose pirarubicin (THP) for six times versus bacillus Calmette-Guérin (BCG) without maintenance therapy after transurethral resection of bladder tumor (TURBT) in patients with primary high-risk non-muscle-invasive bladder cancer (NMIBC). METHODS: We retrospectively evaluated 370 patients with primary high-risk NMIBC who underwent TURBT from November 1993 to April 2019. The patients were divided into two groups: patients treated with intravesical instillation of BCG without maintenance therapy (BCG group) and intensive intravesical instillation of low-dose (20 mg) THP for six times within 10 days after TURBT (THP group) (Figure 1A). Safety was assessed using the Common Terminology Criteria for Adverse Events version 5.0. Background-adjusted multivariate analyses were performed to evaluate the effect of intensive intravesical instillation of low-dose THP on oncological outcomes, including intravesical recurrence-free survival (RFS), upper urinary tract RFS, muscle-invasive bladder cancer-free survival, metastasis-free survival, cancer-specific survival, and overall survival. RESULTS: Of the 370 patients with primary high-risk NMIBC, 180 (49%) and 190 (51%) were stratified into the BCG and THP groups, respectively. The incidence rate of adverse events of any grade in the BCG group was significantly higher than that in the THP group (Figure 1B). In the background-adjusted multivariate analyses, no significant differences were observed in oncological outcomes between the BCG and THP groups (Table 1). CONCLUSIONS: Intensive intravesical instillation of low-dose THP for six times may be one of the treatment options in view of safety and efficacy after TURBT in patients with primary high-risk NMIBC. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e243 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Naoki Fujita More articles by this author Masaki Momota More articles by this author Takuma Narita More articles by this author Hiroyuki Ito More articles by this author Takahiro Yoneyama More articles by this author Yasuhiro Hashimoto More articles by this author Kazuaki Yoshikawa More articles by this author Chikara Ohyama More articles by this author Shingo Hatakeyama More articles by this author Expand All Advertisement PDF downloadLoading ...